CoChat

Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer

Open access

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Purpose: The negative regulatory programmed death-1/programmed death-1 ligand (PD-1/PD-L) pathway in T-cell activation has been suggested to play an important role in tumor evasion from host immunity. In this study, we investigated the expression of PD-L1 and PD-L2 in human esophageal cancer to define their clinical significance in patients' prognosis after surgery. Experimental Design: PD-L1 and PD-L2 gene expression was evaluated in 41 esophagectomy patients by real-time quantitative PCR. The protein expression was also evaluated with newly generated monoclonal antibodies that recognize human PD-L1 (MIH1) and PD-L2 (MIH18). Results: The protein and the mRNA levels of determination by immunohistochemistry and real-time quantitative PCR were closely correlated. PD-L–positive patients had a significantly poorer prognosis than the negative patients. This was more pronounced in the advanced stage of tumor than in the early stage. Furthermore, multivariate analysis indicated that PD-L status was an independent prognostic factor. Although there was no significant correlation between PD-L1 expression and tumor-infiltrating T lymphocytes, PD-L2 expression was inversely correlated with tumor-infiltrating CD8+ T cells. Conclusions: These data suggest that PD-L1 and PD-L2 status may be a new predictor of prognosis for patients with esophageal cancer and provide the rationale for developing novel immunotherapy of targeting PD-1/PD-L pathway.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-04-1469

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 33 references

Cited by

See all 805

Metadata

Authors
Ohigashi, Y., Sho, M., Yamada, Y., Tsurui, Y., Hamada, K., Ikeda, N., Mizuno, T., Yoriki, R., Kashizuka, H., Yane, K., Tsushima, F., Otsuki, N., Yagita, H., Azuma, M., & Nakajima, Y.
Affiliations
  • 1Surgery, Departments of
  • 2Internal Medicine, and
  • Nara Medical University (JP)
  • Tokyo Medical and Dental University (JP)
  • 5Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan
Venue
Clinical Cancer Research
Published
2005-04-15
Volume
11
Issue
8
Pages
2947-2953
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2130207101
Cited by
796
References
33
Citations by year
2026: 7 · 2025: 17 · 2024: 26 · 2023: 36 · 2022: 29 · 2021: 53 · 2020: 71 · 2019: 44 · 2018: 71 · 2017: 86 · 2016: 89 · 2015: 64 · 2014: 47 · 2013: 28 · 2012: 21
FWCI
8.12
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
Japan Society for the Promotion of Science (16591343)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Surgery › Esophageal Cancer Research and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
Keywords
esophageal cancer, PD-L1, PD-L2, tumor immune evasion, prognostic factors, esophagectomy, tumor-infiltrating CD8+ T cells, tumor-infiltrating T cells, immunotherapy, tumor stage
MeSH terms
Aged, Esophageal Neoplasms, Esophagus, Female, Humans, Immunohistochemistry, Male, Membrane Glycoproteins, Middle Aged, Peptides, Prognosis, RNA, Messenger, Antigens, CD, Gene Expression Regulation, Neoplastic, Survival Analysis, B7-1 Antigen, Intercellular Signaling Peptides and Proteins, B7-H1 Antigen, Programmed Cell Death 1 Ligand 2 Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-04-1469
The paper
Ohigashi, Y., Sho, M., Yamada, Y., Tsurui, Y., Hamada, K., Ikeda, N., Mizuno, T., Yoriki, R., Kashizuka, H., Yane, K., Tsushima, F., Otsuki, N., Yagita, H., Azuma, M., & Nakajima, Y. (2005). Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-04-1469

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.